BG106139A - Полиморфи на кристален (2-бензхидрил-1-азабицикло/2.2.2/окт-3-ил)-(5-изопропил-2-метоксибензил)-амин цитрат като nk-1-рецепторни антагонисти - Google Patents

Полиморфи на кристален (2-бензхидрил-1-азабицикло/2.2.2/окт-3-ил)-(5-изопропил-2-метоксибензил)-амин цитрат като nk-1-рецепторни антагонисти Download PDF

Info

Publication number
BG106139A
BG106139A BG106139A BG10613901A BG106139A BG 106139 A BG106139 A BG 106139A BG 106139 A BG106139 A BG 106139A BG 10613901 A BG10613901 A BG 10613901A BG 106139 A BG106139 A BG 106139A
Authority
BG
Bulgaria
Prior art keywords
citrate
monohydrate
crystalline
anhydrous
isopropyl
Prior art date
Application number
BG106139A
Other languages
Bulgarian (bg)
English (en)
Inventor
Stephen MASSETT
George Quallich
Peter Rose
Lewin Wint
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG106139A publication Critical patent/BG106139A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BG106139A 1999-06-01 2001-11-23 Полиморфи на кристален (2-бензхидрил-1-азабицикло/2.2.2/окт-3-ил)-(5-изопропил-2-метоксибензил)-амин цитрат като nk-1-рецепторни антагонисти BG106139A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13699599P 1999-06-01 1999-06-01
PCT/IB2000/000663 WO2000073303A1 (en) 1999-06-01 2000-05-17 Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2.2.2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate as nk-1 receptor antagonists

Publications (1)

Publication Number Publication Date
BG106139A true BG106139A (bg) 2002-05-31

Family

ID=22475353

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106139A BG106139A (bg) 1999-06-01 2001-11-23 Полиморфи на кристален (2-бензхидрил-1-азабицикло/2.2.2/окт-3-ил)-(5-изопропил-2-метоксибензил)-амин цитрат като nk-1-рецепторни антагонисти

Country Status (38)

Country Link
US (1) US6387925B1 (is)
EP (1) EP1181289A1 (is)
JP (1) JP2003501353A (is)
KR (1) KR20020005055A (is)
CN (1) CN1353712A (is)
AP (1) AP2001002350A0 (is)
AR (1) AR029753A1 (is)
AU (1) AU767331B2 (is)
BG (1) BG106139A (is)
BR (1) BR0011125A (is)
CA (1) CA2372236A1 (is)
CO (1) CO5170468A1 (is)
CR (1) CR6513A (is)
CZ (1) CZ20014270A3 (is)
DZ (1) DZ3051A1 (is)
EA (1) EA004206B1 (is)
EE (1) EE200100655A (is)
GT (1) GT200000086A (is)
HK (1) HK1046407A1 (is)
HN (1) HN2000000076A (is)
HR (1) HRP20010884A2 (is)
HU (1) HUP0201798A3 (is)
IL (1) IL145952A0 (is)
IS (1) IS6129A (is)
MX (1) MXPA01012328A (is)
NO (1) NO20015845L (is)
NZ (1) NZ514762A (is)
OA (1) OA11955A (is)
PA (1) PA8496001A1 (is)
PE (1) PE20010155A1 (is)
PL (1) PL352715A1 (is)
SK (1) SK17342001A3 (is)
SV (1) SV2002000092A (is)
TN (1) TNSN00119A1 (is)
TR (1) TR200103472T2 (is)
UY (1) UY26177A1 (is)
WO (1) WO2000073303A1 (is)
ZA (1) ZA200109839B (is)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1551846A1 (en) * 2002-10-04 2005-07-13 Merck Sharp & Dohme Ltd. Azabicyclic spiroether derivatives as receptor antagonists
KR20070094805A (ko) * 2003-06-18 2007-09-21 테바 파마슈티컬 인더스트리즈 리미티드 플루바스타틴 나트륨 결정형 ｘｉｖ, ｌｘｘｉｉｉ,ｌｘｘｉｘ, ｌｘｘｘ 및 ｌｘｘｘｖｉｉ, 이의 제조 방법,이를 포함하는 조성물 및 이를 사용하는 방법
US7371906B2 (en) 2004-08-24 2008-05-13 Eastman Kodak Company Process for photo-oxidative stability improvements
US9446029B2 (en) 2010-07-27 2016-09-20 Colorado State University Research Foundation Use of NK-1 receptor antagonists in management of visceral pain
CN110577522B (zh) * 2018-06-07 2022-12-27 东莞市东阳光动物保健药品有限公司 马罗匹坦柠檬酸盐新晶型及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
CA2102179C (en) * 1991-05-31 1998-10-27 Fumitaka Ito Quinuclidine derivatives
US5886009A (en) * 1992-11-12 1999-03-23 Pfizer Inc. Quinuclidine derivative as a substance P antagonist
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions

Also Published As

Publication number Publication date
BR0011125A (pt) 2002-02-19
IL145952A0 (en) 2002-07-25
JP2003501353A (ja) 2003-01-14
AU4424600A (en) 2000-12-18
HUP0201798A3 (en) 2002-10-28
NO20015845L (no) 2002-01-30
PE20010155A1 (es) 2001-02-08
GT200000086A (es) 2001-11-21
HRP20010884A2 (en) 2003-04-30
SV2002000092A (es) 2002-02-05
DZ3051A1 (fr) 2004-03-27
SK17342001A3 (sk) 2002-10-08
TR200103472T2 (tr) 2002-05-21
AP2001002350A0 (en) 2001-12-31
AU767331B2 (en) 2003-11-06
EE200100655A (et) 2003-02-17
PL352715A1 (en) 2003-09-08
EP1181289A1 (en) 2002-02-27
US6387925B1 (en) 2002-05-14
OA11955A (en) 2006-04-13
MXPA01012328A (es) 2002-07-30
UY26177A1 (es) 2000-12-29
AR029753A1 (es) 2003-07-16
WO2000073303A1 (en) 2000-12-07
EA200100982A1 (ru) 2002-06-27
KR20020005055A (ko) 2002-01-16
NO20015845D0 (no) 2001-11-30
HN2000000076A (es) 2001-02-02
CR6513A (es) 2003-11-25
IS6129A (is) 2001-10-26
EA004206B1 (ru) 2004-02-26
CO5170468A1 (es) 2002-06-27
CN1353712A (zh) 2002-06-12
NZ514762A (en) 2002-12-20
TNSN00119A1 (fr) 2005-11-10
HUP0201798A2 (en) 2002-09-28
CA2372236A1 (en) 2000-12-07
CZ20014270A3 (cs) 2002-08-14
PA8496001A1 (es) 2002-07-30
ZA200109839B (en) 2003-01-29
HK1046407A1 (zh) 2003-01-10

Similar Documents

Publication Publication Date Title
SK391091A3 (en) Crystalline paroxetine hydrochloride hemihydrate, pharmacuetical composition containing the same and its use
US20040220212A1 (en) Zolpidem hemitartrate
CZ78896A3 (en) Crystalline anhydrous micophenolate (of mofetil) and intravenous preparation containing thereof
US6262067B1 (en) Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
US6387925B1 (en) Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
KR100476606B1 (ko) 결정질 아자비시클로(2,2,2)옥탄-3-아민 시트레이트의다형체 및 그의 제약 조성물
SK152095A3 (en) Crystalline (+) l-hydrogentartrate, preparation method thereof, pharmaceutical composition containing its and its use
SK143697A3 (en) A process for preparing form 1 ranitidine hydrochloride
MXPA05001241A (es) Sal acida organica de amilodipina.
TH62655A (th) โพลีมอร์ฟของผลึกอโซไบไซโคล [2,2,2] ออกทาน-3-เอมีน ซิเตรตและองค์ประกอบทางเภสัชกรรมอื่น ๆ
HK1046284B (en) Polymorphs of crystalline azabicyclo(2,2,2) octan-3-aminecitrate and their pharmaceutical compositions